The iconic rise of Viagra has long been a benchmark of pharmaceutical success, however its position within the broader industry now triggers questions about potential gains. Copycat versions are eroding exclusivity , leading to worries that investing in companies significantly dependent to Viagra's once-dominant influence could be a problematic … Read More